Donanemab
- Generic Name
- Donanemab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1931944-80-7
- Unique Ingredient Identifier
- 1ADB65P1KK
- Background
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody targeted against an epitope at the N-terminal of a specific type of amyloid beta (Aβ) - pyroglutamate Aβ - which is found only in the brain amyloid plaques associated with Alzheimer's Disease (AD). It works by inducing microglial-mediated clearance of existing Aβ plaques with the intent of slowing...
- Indication
用于治疗阿尔茨海默病。
- Associated Conditions
- -
- Associated Therapies
- -
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 3060
- Registration Number
- NCT06566170
- Locations
- 🇺🇸
Rehabilitation & Neurological Services, Huntsville, Alabama, United States
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 800
- Registration Number
- NCT05738486
- Locations
- 🇺🇸
Irvine Clinical Research, Irvine, California, United States
🇺🇸Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States
🇺🇸Palm Beach Neurology, West Palm Beach, Florida, United States
A Study of Donanemab (LY3002813) in Healthy Participants
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT05567159
- Locations
- 🇺🇸
ICON Early Phase Services Lenexa Center, Salt Lake City, Utah, United States
A Study of Donanemab (LY3002813) in Healthy Chinese Participants
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT05533411
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1500
- Registration Number
- NCT05508789
- Locations
- 🇪🇸
Fundació ACE, Barcelona, Barcelona [Barcelona], Spain
🇫🇷Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau, Tours, Centre, France
🇵🇱Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Pomorskie, Poland
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
- Conditions
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 148
- Registration Number
- NCT05108922
- Locations
- 🇺🇸
Neurology Center of North Orange County, Fullerton, California, United States
🇺🇸Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States
🇺🇸Conquest Research, Winter Park, Florida, United States
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1823
- Registration Number
- NCT05026866
- Locations
- 🇺🇸
Marvel Clinical Research, Huntington Beach, California, United States
🇺🇸Accel Research Sites - St. Pete-Largo Clinical Research Unit, Largo, Florida, United States
🇺🇸Coram CVS/Specialty Infusion Services - Mendota Heights, Mendota Heights, Minnesota, United States
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 94
- Registration Number
- NCT04640077
- Locations
- 🇺🇸
Bradenton Research Center, Inc., Bradenton, Florida, United States
🇺🇸Merritt Island Medical Research, LLC, Merritt Island, Florida, United States
🇺🇸Boston Center for Memory, Newton, Massachusetts, United States
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1736
- Registration Number
- NCT04437511
- Locations
- 🇺🇸
Kaizen Brain Center, La Jolla, California, United States
🇺🇸Ezy Medical Research, Miami, Florida, United States
🇺🇸Columbus Memory Center, LLC, Columbus, Georgia, United States
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 272
- Registration Number
- NCT03367403
- Locations
- 🇨🇦
Toronto Memory Program, Toronto, Ontario, Canada
🇺🇸Texas Neurology, PA, Dallas, Texas, United States
🇺🇸Bradenton Research Center, Bradenton, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.